SUMMARY

Offer Price

The Offer Price has been determined at HK\$29.15 per Offer Share (excluding brokerage of 1%, the SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%).

Net Proceeds from the Global Offering

Based on the Offer Price of HK\$29.15 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting fees, commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised, is estimated to be approximately HK\$567.3 million. The estimated total listing expenses (based on the final Offer Price) are approximately RMB79.0 million, or 13.3% of the gross proceeds of the Global Offering, comprising underwriting related expenses of approximately RMB23.7 million and non-underwriting related expenses of approximately RMB55.3 million. The Company intends to apply such net proceeds in accordance with the purposes set out in the section headed "Future Plans and Use of Proceeds" in the Prospectus.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$94.2 million for up to 3,368,000 H Shares to be issued upon the exercise of the Over-allotment Option, and such additional net proceeds will be used on a pro-rata basis in accordance with the section headed "Future Plans and Use of Proceeds" in the Prospectus.

Applications under the Hong Kong Public Offering

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been slightly over-subscribed. A total of 668 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and through the **CCASS EIPO** service for a total of 4,740,000 Hong Kong Offer Shares, representing approximately 2.11 times of the total number of 2,246,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering. A total number of 668 successful applicants have been allocated Offer Shares under the Hong Kong Public Offering, 494 of which have been allocated one board lot of H Shares totalling 494,000 H Shares.

As the over-subscription in the Hong Kong Public Offering is less than 15 times, and the Sole Global Coordinator and the Sole Overall Coordinator has decided not to exercise its authority to re-allocate the Offer Shares originally included in the International Offering to the Hong Kong Public Offering in accordance with the Guidance Letter HKEX-GL91-18, the reallocation procedures as described in the section headed "Structure of the Global Offering — The Hong Kong Public Offering — Reallocation and Clawback" in the Prospectus have not been applied.

The final number of Offer Shares comprised in the Hong Kong Public Offering is 2,246,000 Offer Shares, representing approximately 10% of the total number of the Offer Shares initially available under the Global Offering.

International Offering

The Offer Shares initially offered under the International Offering have been slightly oversubscribed, representing approximately 1.38 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 20,209,000 H Shares, representing approximately 90% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 3,368,000 Offer Shares. A total number of 157 placees have been allocated Offer Shares, among which: (i) 140 placees have been allocated with 5 or fewer board lots of H Shares, representing approximately 89.17% of the placees under the International Offering and these placees have been allotted 160,000 H Shares in total, representing approximately 0.79% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 128 placees have been allocated with one board lot of H Shares, representing approximately 81.53% of the placees under the International Offering and these placees have been alloted 128,000 H Shares in total, representing approximately 0.63% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 128 placees have been allocated with one board lot of H Shares, representing approximately 81.53% of the placees under the International Offering and these placees have been alloted 128,000 H Shares in total, representing approximately 0.63% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

Cornerstone Investors

Based on the Offer Price of HK\$29.15 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%), and pursuant to the Cornerstone Investment Agreements, the number of Offer Shares subscribed by the Cornerstone Investors has now been determined. Each of (i) Harvest,(ii) Lingang, and (iii) Jointown International, has subscribed for 2,692,000 Offer Shares, 2,638,000 Offer Shares, and 1,346,000 Offer Shares, respectively, totaling 6,676,000 Offer Shares, representing in aggregate (a) approximately 1.93% of the issued share capital of the Company immediately upon completion of the Global Offering (assuming the Over-allotment Option is not exercised); and (b) approximately 29.73% of the number of Offer Shares under the Global Offering (assuming the Over-allotment Option is not exercised).

As confirmed by each of the Cornerstone Investors, their subscription under the Cornerstone Placing are financed by their own internal resources. To the best knowledge of the Company, (i) each of the Cornerstone Investors is an independent third party and independent of each other, (ii) each of the Cornerstone Investors is not a connected person (as defined in the Listing Rules) of the Company, (iii) none of the Cornerstone Investors is accustomed to take instructions from the Company, the Directors, Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective subsidiaries or their respective close associates; and (iv) none of the subscription of the Company, the Directors, Supervisors, chief executive by the Company, the Directors, Supervisors, chief executive by the Company, the Directors, Supervisors, chief executive, controlling Shareholders, existing Shareholders, substantial Shareholders, existing Shareholders or indirectly by the Company, the Directors, Supervisors, chief executive, controlling Shareholders, existing Shareholders, substantial Shareholders, existing Shareholders, or any of their respective subsidiaries or their respective close associates.

The Offer Shares to be subscribed by the Cornerstone Investors will rank pari passu in all respect with the fully paid H Shares in issue and will count towards the public float of the Company under Rule 8.08 of the Listing Rules. Please refer to the section headed "Cornerstone Investors" in the Prospectus for further details of the Cornerstone Investors.

Connected Client Placee with Consent under Paragraph 5(1) of the Placing Guidelines

Under the International Offering, a total of 982,000 Offer Shares, representing approximately 4.37% of the Offer Shares initially available under the Global Offering, were placed to a connected client of one of the Joint Bookrunners within the meaning of the Placing Guidelines. Details are set out below:

					Approximate
				Approximate	percentage of the
				percentage of the	total issued share
				Offer Shares	capital immediately
		Relationship with	Number of	initially available	following the
	Joint Bookrunner/	the Joint Bookrunner/	Offer Shares	under the	completion of the
Placee	Underwriter	Underwriter	placed	Global Offering ⁽¹⁾⁽²⁾	Global Offering ⁽¹⁾⁽²⁾

Connected client holding Offer Shares on behalf of Independent Third Parties on a non-discretionary basis:

China Galaxy International	China Galaxy International	CGI Investment and CGI	982,000	4.37%	0.28%
Investment Co., Limited	Securities (Hong Kong)	are members of the same			
("CGI Investment")	Co., Limited ("CGI")	group of companies			

Notes:

(1) Assuming the Over-allotment Option is not exercised.

(2) The percentage figures are subject to rounding adjustments.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, consent under paragraph 5(1) of the Placing Guidelines to permit the Company to allocate Offer Shares in the International Offering to the above placee. The Offer Shares placed to the connected client is held by the connected client on behalf of Independent Third Parties and are in compliance with all the conditions under the consent granted by the Stock Exchange.

Save as disclosed in this announcement and confirmed by the Directors, no Offer Shares placed by or through the Sole Global Coordinator, the Sole Overall Coordinator, the Joint Bookrunners or the Underwriters under the Global Offering has been placed with any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.

To the best knowledge of the Directors, no Offer Shares under the International Offering have been allocated to applicants who are core connected persons of the Company, the Directors, the Controlling Shareholders, substantial Shareholders, the existing Shareholders or their respective close associates within the meaning of the Listing Rules whether in their own names or through their nominees and the International Offering is in compliance with the Placing Guidelines. Save as disclosed above, none of the Sole Sponsor, the Sole Overall Coordinator, the Sole Global Coordinator, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering.

The Directors confirm that, to the best of their knowledge, none of the Offer Shares subscribed by the placees or the public has been financed directly or indirectly by the Company, the Directors, Supervisors, chief executives, the Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective subsidiaries or their respective close associates, and none of the placees and the public who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, the Directors, Supervisors, chief executives, the Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the H Shares registered in his/her/its name or otherwise held by him/her/it.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters and the Joint Bookrunners, exercisable by the Sole Global Coordinator and the Sole Overall Coordinator at its sole and absolute discretion for itself and on behalf of the International Underwriters and the Joint Bookrunners, at any time from the Listing Date until Thursday, December 1, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to an aggregate of 3,368,000 additional H Shares, representing not more than 15% of the Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering and such over-allocation will be covered by delayed delivery arrangement with investors who have been offered Offer Shares under the International Offering and such over-allocation will be made on the Company's website at <u>www.scientechmed.com</u> and the website of the Stock Exchange at <u>www.hkexnews.hk</u>. As of the date of this announcement, the Over-allotment Option has not been exercised.

Results of Allocations

The results of allocations and the Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available at the times and dates and in the manner set out below:

• in this announcement to be posted on the websites of the Company and the Stock Exchange at <u>www.scientechmed.com</u> and <u>www.hkexnews.hk</u>, respectively, by no later than 8:00 a.m. on Monday, November 7, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;

- from "IPO Results" function in the **IPO App** or the designated results of allocations website at **www.tricor.com.hk/ipo/result** or **www.hkeipo.hk/IPOResult** with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Monday, November 7, 2022 to 12:00 midnight, on Friday, November 11, 2022; and
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. on Monday, November 7, 2022 to Thursday, November 10, 2022.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed "Results of Applications Made by **HK eIPO White Form**" refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by **HK eIPO White Form**" and "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

Results of allocations of the Hong Kong Offer Shares in the Hong Kong Public Offering, including the final Offer Price, the level of indication of interests in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will also be published on Monday, November 7, 2022 on the Company's website at <u>www.scientechmed.com</u> and the website of the Stock Exchange at <u>www.hkexnews.hk</u>.

Despatch/Collection of H Share Certificates/e-Auto Refund Payment Instructions/Refund Checks

- Applicants who apply for 1,000,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and who have been wholly successfully or partially successfully allocated Hong Kong Offer Shares and are eligible to collect H Share certificates in person may collect H Share certificates from the H Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong from 9:00 a.m. to 1:00 p.m. on Monday, November 7, 2022, or such other date as notified by the Company in the newspapers as the date of despatch/collection of H Share certificates/e-Auto Refund payment instructions/refund cheques.
- H Share certificates for the Hong Kong Offer Shares allotted to applicants who applied for less than 1,000,000 Hong Kong Offer Shares through the **HK eIPO White Form** service are expected to be despatched to those entitled to the address specified in the relevant application instructions through the **HK eIPO White Form** service by ordinary post at their own risk on or before Monday, November 7, 2022.

- Wholly or partially successful applicants who applied by giving electronic application instructions to HKSCC via CCASS will have their H Share certificates issued in the name of HKSCC Nominees and deposited into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants who gave electronic application instructions on their behalf on Monday, November 7, 2022.
- H Share certificates for the Hong Kong Offer Shares allocated to applicants who applied through the **HK eIPO White Form** service which are either not eligible for personal collection or which are eligible but are not collected in person by 1:00 p.m. on Monday, November 7, 2022, are expected to be despatched by ordinary post to those entitled to them at their own risk on or before Monday, November 7, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.
- Applicants who applied through the **HK eIPO White Form** service and paid the application monies from a single bank account will have refund monies (if any) despatched to their application payment accounts in the form of e-Auto Refund payment instructions on Monday, November 7, 2022. Applicants who applied through the **HK eIPO White** Form service and paid the application monies from multiple bank accounts will have refund monies (if any) despatched to the addresses specified on their **HK eIPO White** Form applications in the form of refund check(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post at their own risk on or before Monday, November 7, 2022.
- Refund monies for applicants who have applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants' designated bank accounts or the designated bank accounts of their brokers or custodians on Monday, November 7, 2022.
- H Share certificates will only become valid evidence of title at 8:00 a.m. on the Listing Date which is expected to be Tuesday, November 8, 2022, provided that the Global Offering has become unconditional in all respects at or before that time and the right of termination described in the section headed "Underwriting Hong Kong Underwriting Arrangements Hong Kong Public Offering Grounds for Termination" in the Prospectus has not been exercised.
- The Company will not issue any temporary documents of title in respect of the Offer Shares and will not issue any receipt for application monies received.

Public Float

The Stock Exchange has granted the Company a waiver from strict compliance with the requirements of Rule 8.08(1) of the Listing Rules. Therefore, the minimum percentage of the H Shares from time to time held by the public shall be the higher of (a) 15%; (b) such percentage of Shares held by the public after completion of the Global Offering; and (c) such percentage of Shares held by the public after the exercise of the Over-allotment Option. Immediately following completion of the Global Offering and assuming the Over-allotment Option is not exercised, 52.013.155 H Shares, representing approximately 15.00% of the Company's enlarged issued share capital would be held by the public, which satisfies the minimum percentage prescribed in the conditions imposed in the waiver granted by the Stock Exchange from strict compliance with Rule 8.08(1) of the Listing Rules. The Directors confirm that immediately after the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company, (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules) of the Company, (iii) the three largest public Shareholders do not hold more than 50% of the shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules, and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

Lock-up Obligations

The Company, all existing Shareholders listed out in the table on page 23 in this announcement and the Cornerstone Investors are subject to certain lock-up obligations as set out in the paragraph headed "Lock-up Obligations" in this announcement.

Commencement of Dealings in the H Shares

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. H Share certificates for the Offer Shares will only become valid evidence of title at 8:00 a.m. on Tuesday, November 8, 2022, provided that the Global Offering has become unconditional in all respects and the right of termination as described in the section headed "Underwriting — Hong Kong Underwriting Arrangements — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has not been exercised.

Assuming that the Global Offering becomes unconditional in all aspects at 8:00 a.m. on Tuesday, November 8, 2022 (Hong Kong time), dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Tuesday, November 8, 2022 (Hong Kong time). The H Shares will be traded in board lots of 1,000 H Shares each. The stock code of the H Shares is 2291.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded, and should exercise extreme caution when dealing in H Shares.

OFFER PRICE

The Offer Price has been determined at HK29.15 per Offer Share (excluding brokerage of 1%, the SFC transaction levy of 0.0027%, the Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%).

NET PROCEEDS FROM THE GLOBAL OFFERING

Based on the Offer Price of HK\$29.15 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting fees, commissions and estimated expenses payable by the Company in connection with the Global Offering and assuming the Over-allotment Option is not exercised, are estimated to be approximately HK\$567.3 million. The estimated total listing expenses (based on the final Offer Price) are approximately RMB79.0 million, or 13.3% of the gross proceeds of the Global Offering, comprising underwriting related expenses of approximately RMB23.7 million and non-underwriting related expenses of approximately RMB55.3 million. The Company intends to apply the proceeds from the Global Offering as follows:

- approximately 50.7% of the net proceeds, or approximately HK\$287.6 million, will be used to fund the Company's research and development activities within the next five years;
- approximately 24.3% of the net proceeds, or approximately HK\$137.9 million, will be used for the Company's sales and marketing activities within the next five years;
- approximately 5.0% of the net proceeds, or approximately HK\$28.4 million, will be used to expand the Company's production capacity and strengthen the Company's manufacturing capabilities within the next five years;
- approximately 10.0% of the net proceeds, or approximately HK\$56.7 million, will be used to fund potential strategic investments and acquisitions within the next five years; and
- approximately 10.0% of the net proceeds, or approximately HK\$56.7 million, will be used for the Company's working capital and general corporate purposes.

For further details of the use of proceeds, see "Future Plans and Use of Proceeds" in the Prospectus.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$94.2 million for up to 3,368,000 H Shares upon the exercise of the Overallotment Option, and such additional net proceeds will be used on a pro-rata basis in accordance with the section headed "Future Plans and Use of Proceeds" in the Prospectus.

APPLICATIONS UNDER THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially available under the Hong Kong Public Offering have been slightly over-subscribed. At the close of the application lists at 12:00 noon on Tuesday, November 1, 2022, a total of 668 valid applications have been received pursuant to the Hong Kong Public Offering through the **HK eIPO White Form** service and giving **electronic application instructions** to HKSCC for a total of 4,740,000 Hong Kong Offer Shares, representing approximately 2.11 times of the total number of 2,246,000 Hong Kong Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 660 valid applications in respect of a total of 1,717,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$31.45 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) of HK\$5 million or less, representing approximately 1.53 times of the 1,123,000 Hong Kong Offer Shares initially comprised in Pool A; and
- 8 valid applications in respect of a total of 3,023,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount based on the maximum Offer Price of HK\$31.45 per Offer Share (excluding brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) of more than HK\$5 million, representing approximately 2.69 times of the 1,123,000 Hong Kong Offer Shares initially comprised in Pool B.

No application was rejected due to invalid application. No multiple or suspected multiple applications were identified and rejected. No application was rejected due to dishonored payments. No application for more than 1,123,000 Hong Kong Offer Shares (being 50% of the Hong Kong Offer Shares initially available under the Hong Kong Public Offering) was identified.

A total number of 668 successful applicants have been allocated Offer Shares under the Hong Kong Public Offering, 494 of which have been allocated one board lot of H Shares totalling 494,000 H Shares.

As the over-subscription in the Hong Kong Public Offering is less than 15 times, and the Sole Global Coordinator and the Sole Overall Coordinator has decided not to exercise its authority to re-allocate the Offer Shares originally included in the International Offering to the Hong Kong Public Offering in accordance with the Guidance Letter HKEX-GL91-18, the reallocation procedures as described in the section headed "Structure of the Global Offering — The Hong Kong Public Offering — Reallocation and Clawback" in the Prospectus have not been applied. The final number of Offer Shares comprised in the Hong Kong Public Offering is 2,246,000 Offer Shares, representing approximately 10% of the total number of the Offer Shares initially available under the Global Offering.

The Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed "Basis of Allocation under the Hong Kong Public Offering" below.

INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering have been slightly oversubscribed, representing approximately 1.38 times of the total number of Offer Shares initially available under the International Offering. The final number of Offer Shares under the International Offering is 20,209,000 H Shares, representing approximately 90% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option). There has been an over-allocation of 3,368,000 Offer Shares. A total number of 157 placees have been allocated Offer Shares, among which: (i) 140 placees have been allocated with five or fewer board lots of H Shares, representing approximately 89.17% of the placees under the International Offering and these placees have been allotted 160,000 H Shares in total, representing approximately 0.79% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 128 placees have been allocated with one board lot of H Shares, representing approximately 81.53% of the placees under the International Offering and these placees have been alloted 128,000 H Shares in total, representing approximately 0.63% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised); and (ii) 128 placees have been allocated with one board lot of H Shares, representing approximately 81.53% of the placees under the International Offering and these placees have been alloted 128,000 H Shares in total, representing approximately 0.63% of the Offer Shares initially available under the International Offering (assuming the Over-allotment Option is not exercised).

Cornerstone Investors

Based on the Offer Price of HK\$29.15 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%) and pursuant to the Cornerstone Investment Agreements, as disclosed in the section headed "Cornerstone Investors" in the Prospectus, the number of Offer Shares subscribed for by the Cornerstone Investors has now been determined as set out below:

	Number of H Shares subscribed (rounded down to nearest whole board lot of 1,000 H Shares)	Approximate percentage of Offer Shares in the Global Offering ⁽¹⁾⁽²⁾	Approximate percentage of the total issued share capital immediately following the completion of the Global Offering ⁽¹⁾⁽²⁾
Harvest	2,692,000	11.99%	0.78%
Lingang	2,638,000	11.75%	0.76%
Jointown International	1,346,000	5.99%	0.39%
Total	6,676,000	29.73%	1.93%

Notes:

(1) Assuming that the Over-allotment Option is not exercised.

(2) The percentage figures are subject to rounding adjustments.

As confirmed by each of the Cornerstone Investors, their subscription under the Cornerstone Placing are financed by their own internal resources. To the best knowledge of the Company, (i) each of the Cornerstone Investors is an independent third party and independent of each other, (ii) each of the Cornerstone Investors is not a connected person (as defined in the Listing Rules) of the Company, (iii) none of the Cornerstone Investors is accustomed to take instructions from the Company, the Directors, Supervisors, chief executive, Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their respective subsidiaries or their respective close associates; and (iv) none of the subscription of the relevant Offer Shares by any of the Cornerstone Investors is financed directly or indirectly by the Company, the Directors, Supervisors, chief executive, Controlling Shareholders or any of their respective subsidiaries or any of their respective close associates.

The Cornerstone Placing will form part of the International Offering and the Cornerstone Investors will not subscribe for any Offer Shares under the Global Offering (other than pursuant to the Cornerstone Investment Agreements). The Offer Shares to be subscribed by the Cornerstone Investors will rank pari passu in all respect with the fully paid H Shares in issue and will count towards the public float of the Company under Rule 8.08 of the Listing Rules. Immediately following the completion of the Global Offering, none of the Cornerstone Investors will not have any Board representation in the Company. Other than a guaranteed allocation of the relevant Offer Shares at the final Offer Price, the Cornerstone Investors do not have any preferential rights in the Cornerstone Investment Agreements between the Company and the Cornerstone Investors or any benefit, direct or indirect, conferred on the Cornerstone Investors by virtue of or in relation to the Cornerstone Placing, other than a guaranteed allocation of the relevant Offer Shares at the final Offer Price.

Each of the Cornerstone Investors has agreed that it will not, whether directly or indirectly, at any time during the period of six months from and including the Listing Date (the "Lock-up Period"), (a) dispose of, in any way, any of the Offer Shares purchased pursuant to the relevant Cornerstone Investment Agreement or any interest in any company or entity holding any of the relevant Shares under the relevant Cornerstone Investment Agreement, (b) allow itself to undergo a change of control (as defined in the Takeovers Code) at the level of its ultimate beneficial owner, or (c) enter into any transactions directly or indirectly with the same economic effect as any aforesaid transactions, pursuant to their respective Cornerstone Investment Agreement, save for the limited circumstance where the relevant Shares under the relevant Cornerstone Investment Agreement are transferred to any of its wholly-owned subsidiaries who will be bound by the same obligations of such Cornerstone Investor, including the Lock-up Period restriction.

Please refer to the section headed "Cornerstone Investors" in the Prospectus for further details relating to the Cornerstone Investors.

Connected Client Placee with Consent under Paragraph 5(1) of the Placing Guidelines

Under the International Offering, a total of 982,000 Offer Shares (the "**Relevant Shares**"), representing approximately 4.37% of the Offer Shares initially available under the Global Offering, were placed to a connected client of one of the Joint Bookrunners within the meaning of the Placing Guidelines. Details are set out below:

Joint Bookrunner/ Underwriter	Relationship with the Joint Bookrunner/ Underwriter	Number of Offer Shares placed	Approximate percentage of the Offer Shares initially available under the Global Offering ⁽¹⁾⁽²⁾	Approximate percentage of the total issued share capital immediately following the completion of the Global Offering ⁽¹⁾⁽²⁾
es on behalf of Independent Th	ird Parties on a non-discretionar	v basis:		
China Galaxy International Securities (Hong Kong) Co., Limited ("CGI")	CGI Investment and CGI are members of the same group of companies	982,000	4.37%	0.28%
	Underwriter res on behalf of Independent Th China Galaxy International Securities (Hong Kong)	Joint Bookrunner/ UnderwriterJoint Bookrunner/ Underwriterres on behalf of Independent Third Parties on a non-discretionar, China Galaxy International Securities (Hong Kong)CGI Investment and CGI are members of the same	Joint Bookrunner/ UnderwriterJoint Bookrunner/ UnderwriterOffer Shares placedres on behalf of Independent Third Parties on a non-discretionary basis:CGI Investment and CGI are members of the same982,000	Image: Construction of the construc

Notes:

(1) Assuming the Over-allotment Option is not exercised.

(2) The percentage figures are subject to rounding adjustments.

CGI Investment, a limited company incorporated in Hong Kong, is a wholly-owned subsidiary of China Galaxy International Financial Holdings Limited ("CGIFH"), which is in turn wholly-owned by China Galaxy Securities Co., Ltd. ("CGS"), a limited liability company incorporated in the PRC and ultimately owned by China Investment Corporation, PRC Ministry of Finance and PRC National Council for Social Security Fund. As CGI is also a wholly-owned subsidiary of CGIFH, CGI Investment is therefore a "connected client" of CGI for the purpose of the Placing Guidelines.

As confirmed by CGI Investment, CGS has entered into a master agreement (the "Master Agreement") with CGI Investment to set out the principal terms of any total return swap between CGS and CGI Investment. Beijing Fu'er'te Medical Device Materials Technology Company Limited (北京伏爾特醫療器材科技有限公司) (the "CGS Client") will place a total return swap order (the "Client TRS") with CGS and CGS will place a back-to-back total return swap order (the "Back-to-back TRS", together with the Client TRS, the "OTC Swaps") with CGI Investment under the terms of the Master Agreement. The purposes of the OTC Swaps are to hedge the economic exposure of CGS and CGI Investment in relation to the respective Relevant Shares subscribed by the CGS Client and fully pass through such economic exposure to the CGS Client. CGI Investment will act as the single counterparty of the Back-to-back TRS to be entered into by CGI Investment in connection with the Client TRS to be placed by and fully funded by the CGS Client, subject to the terms and conditions of the OTC Swaps documents, including but not limited to: (1) during the tenor of the OTC Swaps, CGI Investment will hold the title of the respective Relevant Shares on behalf of the CGS Client and pass through the economic return of the same to the CGS Client, and all economic loss will be borne by the CGS Client and CGI Investment will not have any economic exposure in relation to the price of the Relevant Shares; (2) despite that CGI Investment will hold the title of the Relevant Shares, it will not exercise the voting right of the Relevant Shares during the tenor of the OTC Swaps; (3) the OTC Swaps are linked to the Relevant Shares and the CGS Client may request CGS to redeem it at its own discretion, upon which CGI Investment shall dispose of the Relevant Shares and settle OTC Swaps in cash in accordance with the terms and conditions of the OTC Swaps documents; and (4) upon termination of the OTC Swaps, CGI Investment will dispose the Relevant Shares on the secondary market to settle the OTC Swaps, and the CGS Client will receive a final termination amount which would take into account all the economic returns or economic loss in relation to the OTC Swaps, and the fees of the OTC Swaps. As such, CGI Investment will hold the respective Relevant Shares on behalf of the CGS Client on a non-discretionary basis.

The ultimate beneficial owners of Fu'er'te Medical Device are Ran Nianmo (冉年模) and Zhang Ping (張平), who are PRC citizens. Each of the aforementioned ultimate beneficial owners and the CGS Client is an independent third party of CGI Investment.

The Offer Shares placed to the above placee are in compliance with all the conditions under the consent granted by the Stock Exchange. The International Placing is in compliance with the Placing Guidelines. Save as disclosed in this announcement and confirmed by the Directors, no Offer Shares placed by or through the Sole Overall Coordinator, Sole Global Coordinator, the Joint Bookrunners or the Underwriters under the Global Offering has been placed with any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons as set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.

To the best knowledge of the Directors, no Offer Shares under the International Offering have been allocated to applicants who are core connected persons of the Company, the Directors, the Controlling Shareholders, substantial Shareholders, the existing Shareholders or their respective close associates within the meaning of the Listing Rules whether in their own name or through their nominees and the International Offering is in compliance with the Placing Guidelines.

Save as disclosed above, none of the Sole Sponsor, the Sole Overall Coordinator, the Sole Global Coordinator, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering.

The Directors also confirm that, to the best of their knowledge, information and belief, (a) none of the Offer Shares subscribed by the placees and the public has been financed directly or indirectly by the Company, the Directors, the Supervisors, chief executives, the Controlling Shareholders, substantial Shareholders, existing Shareholders or any of their subsidiaries or their respective close associates; and (b) none of the placees and the public who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, the Directors, the Supervisors, chief executives, the Controlling Shareholders, substantial Shareholders, existing Shareholders, substantial Shareholders, existing Shareholders, the Controlling Shareholders, substantial Shareholders, existing Shareholders, or any of their subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Shares registered in his/her/its name or otherwise held by him/her/it.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters and the Joint Bookrunners, exercisable by the Sole Global Coordinator and the Sole Overall Coordinator at its sole and absolute discretion for itself and on behalf of the International Underwriters and the Joint Bookrunners, at any time from the Listing Date until Thursday, December 1, 2022, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering, to require the Company to issue and allot up to an aggregate of 3,368,000 additional H Shares, representing not more than 15% of the Offer Shares initially offered under the Global Offering, at the Offer Price to cover over-allocations in the International Offering and such over-allocation will be covered by delayed delivery arrangement with investors who have been offered Offer Shares under the International Offering. In the event the Over-allotment Option is exercised, an announcement will be made on the Company's website at **www.scientechmed.com** and the website of the Stock Exchange at **www.hkexnews.hk**. As of the date of this announcement, the Over-allotment Option has not been exercised.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed "Structure of the Global Offering — Conditions of the Global Offering" in the Prospectus, 668 valid applications made by the public through the **HK eIPO White Form** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

POOL A

Number of shares	Number of valid		Approximate percentage allotted of the total number of shares applied
applied for	applications	Basis of allocation/ballot	for
1,000	483	1,000 shares	100.00%
2,000	55	1,000 shares plus 44 out of 55 applicants to receive an additional 1,000 shares	90.00%
3,000	37	2,000 shares plus 20 out of 37 applicants to receive an additional 1,000 shares	84.68%
4,000	13	3,000 shares	75.00%
5,000	19	3,000 shares plus 4 out of 19 applicants to receive an additional 1,000 shares	64.21%
6,000	9	3,000 shares plus 5 out of 9 applicants to receive an additional 1,000 shares	59.26%
7,000	3	3,000 shares plus 2 out of 3 applicants to receive an additional 1,000 shares	52.38%
8,000	4	3,000 shares plus 3 out of 4 applicants to receive an additional 1,000 shares	46.88%
9,000	1	4,000 shares	44.44%
10,000	20	4,000 shares plus 4 out of 20 applicants to receive an additional 1,000 shares	42.00%
20,000	8	8,000 shares	40.00%
30,000	3	11,000 shares plus 2 out of 3 applicants to receive an additional 1,000 shares	38.89%
50,000	4	18,000 shares	36.00%
100,000	1	30,000 shares	30.00%
TOTAL:	660	Total number of Pool A successful applicants: 660	

POOL B

Number of shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of shares applied for
200,000	2	74,000 shares plus 1 out of 2 applicants to receive an additional 1,000 shares	37.25%
300,000	5	111,000 shares plus 2 out of 5 applicants to receive an additional 1,000 shares	37.13%
1,123,000	1	417,000 shares	37.13%
TOTAL	8	Total number of Pool B successful applicants: 8	

The final number of Offer Shares comprised in the Hong Kong Public Offering is 2,246,000 Offer Shares, representing approximately 10.0% of the total number of the Offer Shares initially available under the Global Offering. The final number of Offer Shares comprised in the International Offering is 20,209,000 Offer Shares, representing approximately 90.0% of the total number of the Offer Shares initially available under the Global Offering, assuming the Over-allotment Option is not exercised.

RESULTS OF ALLOCATIONS

The results of allocations and the Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available at the times and dates and in the manner set out below:

- in this announcement to be posted on the websites of the Company and the Stock Exchange at www.scientechmed.com and www.hkexnews.hk, respectively, by no later than 8:00 a.m. on Monday, November 7, 2022. Please note that the list of identification document numbers in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Offer Shares through their brokers can consult their brokers to enquire about their application result;
- from "IPO Results" function in the IPO App or the designated results of allocations website at <u>www.tricor.com.hk/ipo/result</u> or <u>www.hkeipo.hk/IPOResult</u> with a "search by ID" function on a 24-hour basis from 8:00 a.m. on Monday, November 7, 2022 to 12:00 midnight, on Friday, November 11, 2022; and
- from the allocation results telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. on Monday, November 7, 2022 to Thursday, November 10, 2022.

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed "Results of Applications Made by **HK eIPO White Form**" refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by **HK eIPO White Form**" and "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

Results of allocations of the Hong Kong Offer Shares in the Hong Kong Public Offering, including the final Offer Price, the level of indication of interests in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares will also be published on Monday, November 7, 2022 on the Company's website at **www.scientechmed.com** and the website of the Stock Exchange at **www.hkexnews.hk**.

SHAREHOLDING CONCENTRATION ANALYSIS

We set out below a summary of allotment results under the Global Offering:

• Top 1, 5, 10, 20 and 25 of the placees in the International Offering:

Placee	Subscription	H Shares held following the Global Offering	Subscription as % of International Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription as % of International Offer Shares (assuming the Over-allotment Option is fully exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is fully exercised)	% of the total issued Shares (assuming the Over-allotment Option is not exercised)	% of the total issued Shares (assuming the Over-allotment Option is fully exercised)
Top 1	2,692,000	2,692,000	13.32%	11.42%	11.99%	10.42%	0.78%	0.77%
Top 5	13,406,000	13,406,000	66.34%	56.86%	59.70%	51.91%	3.87%	3.83%
Top 10	20,004,000	20,004,000	98.99%	84.85%	89.08%	77.47%	5.77%	5.71%
Top 20	23,427,000	23,427,000	115.92%	99.36%	104.33%	90.72%	6.76%	6.69%
Top 25	23,441,000	23,441,000	115.99%	99.42%	104.39%	90.78%	6.76%	6.70%

• Top 1, 5, 10, 20 and 25 of all the holders of the H Shares⁽¹⁾ of the Company upon Listing:

				Subscription as % of the total number of H Shares allocated under the International Offering (assuming the	Subscription as % of the total number of H Shares allocated under the International Offering (assuming the	Subscription as % of the total number of H Shares allocated under the Global Offering assuming the	Subscription as % of the total number of H Shares allocated under the Global Offering (assuming the	H Shares held as % of total number of H Shares immediately following the Global Offering (assuming the	H Shares held as % of total number of H Shares immediately following the Global Offering (assuming the	H Shares held as % of total share capital in issue (assuming the	H Shares held as % of total share capital in issue (assuming the
H Shareholder	Subscription	Shares held upon Listing	H Shares held upon Listing	Over-allotment Option is not exercised) ⁽²⁾		Over-allotment Option is not exercised)	Over-allotment Option is fully exercised)	Over-allotment Option is not exercised)	Over-allotment Option is fully exercised)	Over-allotment Option is not exercised)	Over-allotment Option is fully exercised)
H Shareholder Top 1	Subscription			Option is not	Option is fully	Option is not	Option is fully	Option is not	Option is fully	Option is not	Option is fully
	Ĩ	upon Listing	upon Listing	Option is not exercised) ⁽²⁾	Option is fully exercised) ⁽²⁾	Option is not exercised)	Option is fully exercised)	Option is not exercised)	Option is fully exercised)	Option is not exercised)	Option is fully exercised)
Top 1	-	upon Listing 280,000,000	upon Listing 280,000,000	Option is not exercised) ²⁾ 0.00%	Option is fully exercised) ⁽²⁾ 0.00%	Option is not exercised) 0.00%	Option is fully exercised) 0.00%	Option is not exercised) 80.75%	Option is fully exercised) 79.97%	Option is not exercised) 80.75%	Option is fully exercised) 79.97%
Top 1 Top 5	-	upon Listing 280,000,000 319,628,609	upon Listing 280,000,000 319,628,609	Option is not exercised) ⁽²⁾ 0.00% 0.00%	Option is fully exercised) ⁽²⁾ 0.00% 0.00%	Option is not exercised) 0.00% 0.00%	Option is fully exercised) 0.00% 0.00%	Option is not exercised) 80.75% 92.18%	Option is fully exercised) 79.97% 91.29%	Option is not exercised) 80.75% 92.18%	Option is fully exercised) 79.97% 91.29%

Notes:

- (1) Given all the Domestic Shares and Unlisted Foreign Shares of the Company will be converted into H Shares upon completion of the Global Offering, the share capital of the Company shall consist of H Shares only. Therefore, the holders of the H Shares will be the Shareholders of the Company upon Listing.
- (2) It represents the subscription level as percentage of the total number of H Shares allocated under the International Offering without taking into account the subscription by successful applicants under the Hong Kong Public Offering.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded, and should exercise extreme caution when dealing in H Shares.